Indeed, liraglutide, a first-line treatment for type 2 diabetes, has been reported to reduce inflammation and HFD-induced MASLD by modulating Kupffer cell M2 polarization through the STAT3 signaling pathway (38). Here, STAT3 is linked to metabolic dysfunction-associated steatotic liver disease.